Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Zemp, Franz J ^a   McKenzie, Brienne A ^a   Lun, Xueqing ^a   Maxwell, Lori ^a   Reilly, Karlyne M ^b   McFadden, Grant ^c   Yong, V Wee ^d   Forsyth, Peter A ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 9; NEUROFIBROMIN; ONCOLYTIC MYXOMA VIRUS; PROTEIN P53; UNCLASSIFIED DRUG; VIROTHERAPY AGENT; IRF9 PROTEIN, MOUSE; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PROTEIN FUNCTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DISEASE RESISTANCE; DRUG SCREENING; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; ISOGRAFT; MYXOMA VIRUS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS; MYXOMA VIRUS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; FEMALE; GLIOMA; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYXOMA VIRUS; NEUROFILAMENT PROTEINS; ONCOLYTIC VIROTHERAPY; TRANSPLANTATION, ISOGENEIC; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878811622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065801     Document Type: Article

References (56)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Wen PY, Kesari S, (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
3. Oertel J, von Buttlar E, Schroeder HW, Gaab MR, (2005) Prognosis of gliomas in the 1970s and today. Neurosurg Focus 18: e12.
4. Wollmann G, Ozduman K, van den Pol AN, (2012) Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 18: 69-81.
5. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA, (2010) Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 21: 103-117.
6. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, et al. (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
7. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, et al. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398-406.
8. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65: 9982-9990.
9. Lun XQ, Zhou H, Alain T, Sun B, Wang L, et al. (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 67: 8818-8827.
10. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, et al. (2010) Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 70: 598-608.
11. Wennier S, Li S, McFadden G, (2011) Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med 13: e18.
12. Wennier ST, Liu J, Li S, Rahman MM, Mona M, et al. (2012) Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther 20: 759-768.
13. Barth RF, Kaur B, (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 94: 299-312.
14. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T, (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26: 109-113.
15. Reilly K (2009) The Nf1-/+{thorn}; Trp53-/+cis Mouse Model of Anaplastic Astrocytoma and Secondary Glioblastoma: Dissecting Genetic Susceptibility to Brain Cancer. 2009 ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Appoaches: Springer. pp. 93-118.
16. Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, et al. (2004) Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A 101: 13008-13013.
17. Gursel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, et al. (2011) Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro Oncol 13: 610-621.
18. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
19. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
20. Lun X, Chan J, Zhou H, Sun B, Kelly JJ, et al. (2010) Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 18: 1927-1936.
21. Hellums EK, Markert JM, Parker JN, He B, Perbal B, et al. (2005) Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 7: 213-224.
22. Paul S, Ricour C, Sommereyns C, Sorgeloos F, Michiels T, (2007) Type I interferon response in the central nervous system. Biochimie 89: 770-778.
23. Christensen JE, Fenger C, Issazadeh-Navikas S, Krug A, Liljestrom P, et al. (2012) Differential impact of interferon regulatory factor 7 in initiation of the type I interferon response in the lymphocytic choriomeningitis virus-infected central nervous system versus the periphery. J Virol 86: 7384-7392.
24. Savarin C, Bergmann CC, (2008) Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. Curr Opin Pharmacol 8: 472-479.
25. Uze G, Lutfalla G, Bandu MT, Proudhon D, Mogensen KE, (1992) Behavior of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background. Proc Natl Acad Sci U S A 89: 4774-4778.
26. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J, (2001) Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther 4: 356-364.
27. Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, et al. (2001) Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 108: 83-95.
28. Zemp F, Lun X, McKenzie B, Zhou H, Maxwell L, et al. (2013) Treating Brain Tumor-Initiating Cells Using a Combination of Myxoma Virus and Rapamycin. Neuro Oncol doi: 10.1093/neuonc/not035.
29. Smallwood SE, Rahman MM, Smith DW, McFadden G, (2010) Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol Chapter 14: Unit 14A 11.
30. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, et al. (2010) Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 107: 1576-1581.
31. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, et al. (2009) Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 27: 1722-1733.
32. (2000) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press.
33. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
34. Paulus W, Huettner C, Tonn JC, (1994) Collagens, integrins and the mesenchymal drift in glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures. Int J Cancer 58: 841-846.
35. McKeever PE, Davenport RD, Shakui P, (1991) Patterns of antigenic expression of human glioma cells. Crit Rev Neurobiol 6: 119-147.
36. France MR, Thomas DL, Liu J, McFadden G, MacNeill AL, et al. (2011) Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells. J Gen Virol 92: 195-199.
37. Collins SE, Noyce RS, Mossman KL, (2004) Innate cellular response to virus particle entry requires IRF3 but not virus replication. J Virol 78: 1706-1717.
38. Noyce RS, Taylor K, Ciechonska M, Collins SE, Duncan R, et al. (2011) Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response. J Virol 85: 10926-10931.
39. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
40. Ohgaki H, Kleihues P, (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453.
41. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL, (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
42. Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, et al. (1996) Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 55: 1259-1269.
43. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504.
44. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509.
45. Gray PW, Goeddel DV, (1983) Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci U S A 80: 5842-5846.
46. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281: 13964-13971.
47. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
48. Balachandran S, Barber GN, (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5: 51-65.
49. Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, et al. (2009) Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett 284: 71-79.
50. Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, et al. (2005) Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol 74: 249-260.
51. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, et al. (2011) Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730.
52. Wang F, Ma Y, Barrett JW, Gao X, Loh J, et al. (2004) Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 5: 1266-1274.
53. Cantin E, Tanamachi B, Openshaw H, (1999) Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J Virol 73: 3418-3423.
54. Kastrukoff LF, Lau AS, Thomas EE, (2012) The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS). Herpesviridae 3: 4.
55. Lando Z, Teitelbaum D, Arnon R, (1980) Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice. Nature 287: 551-552.
56. Gold R, Linington C, Lassmann H, (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971.